BROADWOOD PARTNERS L.P. 13D and 13G filings for OncoCyte Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-10 8:46 pm Purchase | 2025-02-06 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 11,560,350 40.200% | 6,481,034 (+127.60%) | Filing |
| 2024-04-15 7:26 pm Purchase | 2024-04-11 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 5,079,316 37.600% | 5,079,316 (New Position) | Filing |